A video game for ADHD? We’re still waiting to see what the FDA thinks

| | January 24, 2020
akili project evo
Image: Akili
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

In mid-2018, the startup Akili Interactive Labs asked the Food and Drug Administration to let it do something that’s never been done before: market a video game that physicians would prescribe to kids with ADHD.

A year and a half later, that green light has yet to materialize. It’s unclear whether that’s a sign of trouble — the company wouldn’t say whether the agency has asked it to make changes or run a new study — or simply a reflection of the complexity of evaluating a medical product without precedent.

Akili’s CEO, Eddie Martucci, told STAT the company is having ongoing discussions with regulators. He said Akili believes it has studied its game rigorously.

Related article:  Night shift workers are at greater risk for obesity, diabetes, cancer—but why?

Akili’s video game is played on a tablet. It sends players through landscapes like a molten lava river and an icy winter snowscape, rewarding them with stars and points as they finish tasks. Akili sees the video game as the delivery system for targeted algorithms that can activate certain neural networks in the brain.

[ADHD specialist Sandra] Loo said she expects that if Akili’s game comes to market, it will be prescribed using a precision medicine approach to only those patients likely to benefit, rather than to all kids with ADHD.

Read original post

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend